For patients with advanced NSCLC with tumor proportional score(TPS) of PD-L1 ≥ 1%, immune monotherapy can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients compared with chemotherapy, especially for patients with TPS ≥ 50%, while immunotherapy combined with chemotherapy significantly prolonged PFS and OS of patients with PD-L1 negative and driver-gene-negative advanced non-squamous NSCLC [7–10]. Here, CD274 is linked to neoplasm.